Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | STAT6 | P42226 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6590103 | 0.98 | LMNA (0.57) | LMNACYP2C9KDM4EABCB11ESR1 | |
| SCHEMBL2959744 | 0.83 | ELANE (0.57) | LMNACYP2C9KDM4EABCB11ESR1 | |
| SCHEMBL29177459 | 0.82 | CYP1A2 (0.51) | CYP2C9CYP1A2CYP2D6CYP19A1CYP2C19 | |
| SCHEMBL4986100 | 0.82 | ELANE (0.56) | LMNACYP2C9KDM4EABCB11ESR1 | |
| SCHEMBL6842392 | 0.82 | ELANE (0.56) | LMNACYP2C9KDM4EABCB11ESR1 | |
| SCHEMBL4688782 | 0.81 | MAPT (0.52) | LMNACYP2C9KDM4EABCB11ESR1 | |
| SCHEMBL6832448 | 0.80 | CYP2C9 (0.50) | LMNACYP2C9KDM4EABCB11ESR1 | |
| SCHEMBL18573395 | 0.79 | MAPT (0.60) | CYP2C9KDM4ECYP1A2CYP2D6CYP19A1 | |
| SCHEMBL27916227 | 0.79 | KDM4E (0.50) | LMNACYP2C9KDM4EABCB11ESR1 | |
| SCHEMBL29399270 | 0.79 | HSD17B10 (0.71) | LMNACYP2C9CYP1A2CYP2C19ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168576-A2 | New utilities of tricyclic compounds | Shionogi & Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20080318958-A1 | New utilities of tricyclic compounds | ISHIZUKA NATSUKI | 2008-12-25 | — | — | US | disclosed |
| US-20080318958-A1 | New utilities of tricyclic compounds | ISHIZUKA NATSUKI | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318958-A1 | New utilities of tricyclic compounds | APOB, PON1, APOL1 | LMNA 920/4885CYP2C9 342/4885KDM4E 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.